Blockchain Registration Transaction Record

Telomir-Zn Shows Promise in Wilson’s Disease Study

Telomir Pharmaceuticals publishes preclinical data showing Telomir-Zn improves survival and reduces oxidative stress in Wilson's disease model, advancing its cancer program.

This news matters because it demonstrates Telomir-Zn's potential to address Wilson’s disease, a rare genetic disorder with limited treatment options. The preclinical data showing reduced oxidative stress and copper burden could pave the way for new therapies. Moreover, the findings bolster Telomir Pharmaceuticals' broader pipeline, including its triple-negative breast cancer program, offering hope for patients with hard-to-treat conditions.